1. Home
  2. ARMP vs BMHL Comparison

ARMP vs BMHL Comparison

Compare ARMP & BMHL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ARMP
  • BMHL
  • Stock Information
  • Founded
  • ARMP N/A
  • BMHL 2016
  • Country
  • ARMP United States
  • BMHL Hong Kong
  • Employees
  • ARMP N/A
  • BMHL N/A
  • Industry
  • ARMP Biotechnology: Biological Products (No Diagnostic Substances)
  • BMHL
  • Sector
  • ARMP Health Care
  • BMHL
  • Exchange
  • ARMP Nasdaq
  • BMHL Nasdaq
  • Market Cap
  • ARMP 104.3M
  • BMHL 96.0M
  • IPO Year
  • ARMP N/A
  • BMHL 2025
  • Fundamental
  • Price
  • ARMP $3.12
  • BMHL $3.70
  • Analyst Decision
  • ARMP Strong Buy
  • BMHL
  • Analyst Count
  • ARMP 1
  • BMHL 0
  • Target Price
  • ARMP $9.00
  • BMHL N/A
  • AVG Volume (30 Days)
  • ARMP 7.8K
  • BMHL 5.1K
  • Earning Date
  • ARMP 11-12-2025
  • BMHL 01-01-0001
  • Dividend Yield
  • ARMP N/A
  • BMHL N/A
  • EPS Growth
  • ARMP N/A
  • BMHL 9.50
  • EPS
  • ARMP N/A
  • BMHL 0.05
  • Revenue
  • ARMP $6,868,000.00
  • BMHL $6,873,097.00
  • Revenue This Year
  • ARMP $8.43
  • BMHL N/A
  • Revenue Next Year
  • ARMP N/A
  • BMHL N/A
  • P/E Ratio
  • ARMP N/A
  • BMHL $68.51
  • Revenue Growth
  • ARMP 84.67
  • BMHL 66.02
  • 52 Week Low
  • ARMP $0.90
  • BMHL $3.37
  • 52 Week High
  • ARMP $3.14
  • BMHL $4.49
  • Technical
  • Relative Strength Index (RSI)
  • ARMP 62.83
  • BMHL N/A
  • Support Level
  • ARMP $2.94
  • BMHL N/A
  • Resistance Level
  • ARMP $3.07
  • BMHL N/A
  • Average True Range (ATR)
  • ARMP 0.08
  • BMHL 0.00
  • MACD
  • ARMP -0.01
  • BMHL 0.00
  • Stochastic Oscillator
  • ARMP 97.96
  • BMHL 0.00

About ARMP Armata Pharmaceuticals Inc.

Armata Pharmaceuticals Inc is a developer of pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. The company is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other pathogens. In addition, in collaboration with Merck, the company is developing proprietary synthetic phage candidates to target an undisclosed infectious disease agent.

About BMHL Bluemount Holdings Limited Class B Ordinary Shares

Bluemount Holdings Ltd through its operating subsidiaries, it is a Hong Kong-based consulting and advisory and financial services provider, as well as trader of commodities such as luxury timepieces. The financial services includes underwriting and placing services, securities dealing and brokerage services, and asset management services. It provides comprehensive consulting and advisory services on business development strategies to its diverse clientele. Generally, the company provides consulting and advisory business for the following segments: Corporate Finance; and Strategic Communications.

Share on Social Networks: